多替拉韦与依非韦伦对免疫恢复标志物影响的随机临床试验
该研究为SINGLE试验的事后探索性分析,比较多替拉韦/阿巴卡韦/拉米夫定与依非韦伦/替诺福韦/恩曲他滨起始治疗后免疫恢复标志物的差异。结果显示,第96周时依非韦伦组CD4/CD8比值≥1的比例更高(差异11.70,95%CI 4.49-18.91,p=0.002),且完全T细胞标志物恢复(MTMR)比例更高(p=0.001)。
要点
- 第96周时依非韦伦组CD4/CD8比值≥1的比例显著高于多替拉韦组。
- 依非韦伦组CD8+细胞计数下降幅度更大。
- 两组CD4%变化无显著差异,MTMR差异仅在第96周有统计学意义。
核心结论
- 依非韦伦/替诺福韦/恩曲他滨组在治疗96周后CD4/CD8比值≥1.0或MTMR的增幅显著大于多替拉韦/阿巴卡韦/拉米夫定组。
- 需进一步研究以理解这些发现的临床影响。
研究设计与样本
- SINGLE研究的事后探索性分析,该研究为随机双盲临床试验。
- 共分析833名参与者,其中414名接受多替拉韦/阿巴卡韦/拉米夫定。
主要发现
- 第48周和第96周CD4/CD8比值≥0.5的比例无统计学显著差异。
- 第96周CD4/CD8比值≥1的比例在依非韦伦/替诺福韦/恩曲他滨组更高(差异11.70,95%CI 4.49-18.91,p=0.002)。
- 依非韦伦/替诺福韦/恩曲他滨组CD8+细胞计数较基线的下降持续更大。
- CD4+百分比分析显示研究期间无显著差异。
- MTMR比例在依非韦伦/替诺福韦/恩曲他滨组更高,但差异仅在第96周有统计学意义(p=0.001)。
关键数值与推荐
- CD4/CD8比值≥0.5:第48周和第96周两组无显著差异。
- CD4/CD8比值≥1:第96周依非韦伦/替诺福韦/恩曲他滨组更高,差异11.70(95%CI 4.49-18.91),p=0.002。
- MTMR:第96周依非韦伦/替诺福韦/恩曲他滨组更高,p=0.001。
临床怎么用
- 在评估HIV起始治疗方案的免疫恢复时,除病毒学抑制外,可关注CD4/CD8比值和MTMR等标志物。
- 依非韦伦/替诺福韦/恩曲他滨在CD4/CD8比值≥1和MTMR方面可能更具优势,但需结合临床综合判断。
局限性
- 该分析为事后探索性分析,并非研究主要终点。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: CD4/CD8 ratio and CD4+ T-cell percentage (CD4%) predicts the risk of AIDS and non-AIDS events. Multiple T-cell marker recovery (MTMR) has been proposed as the most complete level of immune reconstitution. We quantified differences in the CD4/CD8 ratio, CD4% recovery and MTMR after starting HIV-1 treatment with dolutegravir/abacavir/lamivudine vs. efavirenz (EFV)/tenofovir (TDF)/emtricitabine (FTC). METHODS: Exploratory post hoc analysis of the SINGLE study, a randomized double-blind, clinical trial. Percentage differences and corresponding precision based on 95% confidence intervals, and p values were calculated for CD4/CD8 ratio normalization, CD4% normalization and the achievement of MTMR. Cox models taking into account competing risks were used to estimate sub-hazard ratios when comparing the times to normalization of the CD4/CD8 ratio and the CD4% by treatment arm. RESULTS: Data from 833 participants were analysed (414 in the dolutegravir/abacavir/lamivudine arm). There were no statistically significant differences in the proportion of patients who reached a CD4/CD8 ratio ≥0.5 at weeks 48 and 96. However, at week 96, the proportion of patients with a CD4/CD8 ratio ≥1 was higher in the EFV-TDF-FTC group (difference, 11.70; 95% confidence interval, 4.49-18.91; p 0.002). The decrease from baseline in CD8+ cell count was consistently greater in the EFV-TDF-FTC arm. Analysis of CD4+ percentages showed no significant differences during the study. The proportion of patients attaining a MTMR was higher in the EFV-TDF-FTC group, although the difference was only statistically significant at week 96 (p 0.001). CONCLUSIONS: EFV-TDF-FTC showed significantly greater increases in CD4/CD8 ratio ≥1.0 or MTMR beyond treatment week 96. Additional studies are necessary to better understand the impact of these findings.
引用
- Blanco JR, Alejos B, Moreno S, et al. Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial. Clin Microbiol Infect. 2017. PMID: 29183782. doi:10.1016/j.cmi.2017.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。